argenx NV ADR (ARGX)vsRani Therapeutics Holdings Inc (RANI)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
RANI
Rani Therapeutics Holdings Inc
$1.14
+7.55%
HEALTHCARE · Cap: $139.82M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 352939% more annual revenue ($4.24B vs $1.20M). ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
RANI
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for RANI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -11.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : RANI
The strongest argument for RANI centers on Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while RANI is a value play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.41 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 17/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is an innovative biotechnology company focused on transforming the delivery of injectable therapeutics with its cutting-edge RaniPill™ technology, facilitating the oral administration of biologics. This proprietary platform is designed to enhance patient adherence and improve treatment outcomes, addressing key unmet needs in the healthcare sector. With a robust and diverse pipeline across various therapeutic areas, Rani Therapeutics is poised to disrupt traditional drug delivery systems while capitalizing on the growing demand for non-invasive alternatives. The company’s strategic partnerships and unwavering commitment to research and development underscore its potential for sustainable growth and significant impact within the pharmaceutical industry.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?